After Jenny Pearson’s daughter Elise first had a seizure at 16 months old, an MRI came back clean—her brain “looked beautiful ...
GSK, Roche and Novartis continued Big Pharma's dealmaking spree with Asian companies. Three midsized Asian biopharmas reached ...
The product pull—which covers three U.S.-distributed batches of multidose epinephrine vials for injection—follows customer ...
The 2026 Fierce 50 includes people and organizations working on very different problems across biopharma and healthcare, from de | In this week’s episode of “The Top Line,” we look at the people who ...
Following a string of customer complaints, a Form 483 and a recall this past spring, a Fresenius manufacturing unit in Utah ...
Novartis is taking social media by storm with a multiple sclerosis (MS) campaign that urges patients to #KnowYourMS, a ...
While a positive advisory committee meeting seemed to up the odds of approval for Replimune’s twice-snubbed melanoma drug in ...
About two years ago, a head-to-head progression-free survival win made Akeso and Summit Therapeutics’ ivonescimab—and the ...
Repatha, also known as evolocumab, was first approved by the FDA in 2015 to help patients lower their LDL, or “bad,” ...
Since the launch of the Medicare GLP-1 Bridge on July 1, over 500,000 seniors have utilized the program and together saved ...
Following a blow to the integrated contract developer and manufacturer’s client base, Cellares continues to move forward with ...
Some four months after the White House inked the last of its expected drug pricing deals with 17 of the industry’s top ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results